459 Studies Now Enrolling
HORIZON: A Phase II, Open-label, Outcomes-assessor Masked, Multicentre, Randomised, Controlled Study to Evaluate the Safety and Efficacy of Two Doses of GT005 Administered as a Single Subretinal Injection in Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration
HORIZON: Gene Therapy for Dry Age-Related Macular Degeneration
| Sponsor: | Gyroscope Therapeutics |
| Enrolling: | Male and Female Patients |
| Study Length: | 1 Years |
| Clinic Visits: | 10 |
| IRB Number: | AAAT1103 |
| U.S. Govt. ID: | NCT04566445 |
| Contact: | Edylin Ma Bautista: 212-342-4586 / eyetrials@columbia.edu |
Additional Study Information:
The purpose of this clinical study is to evaluate the safety and efficacy of two doses of GT005 administered as a single subretinal injection in individuals with geographic atrophy secondary to dry age-related macular degeneration (AMD) who qualify, based on genetic testing.
This study is closed
Do You Qualify?
| Do you have a clinical diagnosis of dry macular degeneration? | Yes | No |
| Are you willing to give written, informed consent to enroll in the study? | Yes | No |
| Are you able to attend 10 study visits and complete the study procedures? | Yes | No |
| Are you willing to provide a saliva and blood sample for genetic testing? | Yes | No |
| Have you received cell or gene therapy of any kind? | Yes | No |